184 related articles for article (PubMed ID: 30417424)
1. BET inhibitors reduce cell size and induce reversible cell cycle arrest in AML.
Zhang S; Zhao Y; Heaster TM; Fischer MA; Stengel KR; Zhou X; Ramsey H; Zhou MM; Savona MR; Skala MC; Hiebert SW
J Cell Biochem; 2019 May; 120(5):7309-7322. PubMed ID: 30417424
[TBL] [Abstract][Full Text] [Related]
2. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.
Li W; Gupta SK; Han W; Kundson RA; Nelson S; Knutson D; Greipp PT; Elsawa SF; Sotomayor EM; Gupta M
J Hematol Oncol; 2019 Jul; 12(1):73. PubMed ID: 31288832
[TBL] [Abstract][Full Text] [Related]
3. The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation.
Amari K; Sasagawa S; Imayoshi N; Toda Y; Hosogi S; Imamura T; Ashihara E
Biochem Biophys Res Commun; 2022 Jan; 588():147-153. PubMed ID: 34954522
[TBL] [Abstract][Full Text] [Related]
4. Lactate Utilization Enables Metabolic Escape to Confer Resistance to BET Inhibition in Acute Myeloid Leukemia.
Monteith AJ; Ramsey HE; Silver AJ; Brown D; Greenwood D; Smith BN; Wise AD; Liu J; Olmstead SD; Watke J; Arrate MP; Gorska AE; Fuller L; Locasale JW; Stubbs MC; Rathmell JC; Savona MR
Cancer Res; 2024 Apr; 84(7):1101-1114. PubMed ID: 38285895
[TBL] [Abstract][Full Text] [Related]
5. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma.
Bhadury J; Nilsson LM; Muralidharan SV; Green LC; Li Z; Gesner EM; Hansen HC; Keller UB; McLure KG; Nilsson JA
Proc Natl Acad Sci U S A; 2014 Jul; 111(26):E2721-30. PubMed ID: 24979794
[TBL] [Abstract][Full Text] [Related]
6. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L
Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.
Saenz DT; Fiskus W; Mill CP; Perera D; Manshouri T; Lara BH; Karkhanis V; Sharma S; Horrigan SK; Bose P; Kadia TM; Masarova L; DiNardo CD; Borthakur G; Khoury JD; Takahashi K; Bhaskara S; Lin CY; Green MR; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
Blood; 2020 Apr; 135(15):1255-1269. PubMed ID: 32068780
[TBL] [Abstract][Full Text] [Related]
8. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.
Stewart HJ; Horne GA; Bastow S; Chevassut TJ
Cancer Med; 2013 Dec; 2(6):826-35. PubMed ID: 24403256
[TBL] [Abstract][Full Text] [Related]
9. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
Fiskus W; Sharma S; Qi J; Valenta JA; Schaub LJ; Shah B; Peth K; Portier BP; Rodriguez M; Devaraj SG; Zhan M; Sheng J; Iyer SP; Bradner JE; Bhalla KN
Mol Cancer Ther; 2014 May; 13(5):1142-54. PubMed ID: 24435446
[TBL] [Abstract][Full Text] [Related]
10. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
[TBL] [Abstract][Full Text] [Related]
11. Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML).
Djamai H; Berrou J; Dupont M; Coudé MM; Delord M; Clappier E; Marceau-Renaut A; Kaci A; Raffoux E; Itzykson R; Berthier C; Wu HC; Hleihel R; Bazarbachi A; de Thé H; Baruchel A; Gardin C; Dombret H; Braun T
Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829934
[TBL] [Abstract][Full Text] [Related]
12. BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells.
Rossi T; Zamponi R; Chirico M; Pisanu ME; Iorio E; Torricelli F; Gugnoni M; Ciarrocchi A; Pistoni M
J Exp Clin Cancer Res; 2023 Jan; 42(1):7. PubMed ID: 36604676
[TBL] [Abstract][Full Text] [Related]
13. Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4.
Calder J; Nagelberg A; Luu J; Lu D; Lockwood WW
Oncogenesis; 2021 Mar; 10(3):27. PubMed ID: 33712563
[TBL] [Abstract][Full Text] [Related]
14. Monocytic differentiation and AHR signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia.
Romine KA; Nechiporuk T; Bottomly D; Jeng S; McWeeney SK; Kaempf A; Corces MR; Majeti R; Tyner JW
Blood Cancer Discov; 2021 Sep; 2(5):518-531. PubMed ID: 34568834
[TBL] [Abstract][Full Text] [Related]
15. Disruption of CTCF Boundary at HOXA Locus Promote BET Inhibitors' Therapeutic Sensitivity in Acute Myeloid Leukemia.
Zha J; Lai Q; Deng M; Shi P; Zhao H; Chen Q; Wu H; Xu B
Stem Cell Rev Rep; 2020 Dec; 16(6):1280-1291. PubMed ID: 33057942
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies.
Lasorsa E; Smonksey M; Kirk JS; Rosario S; Hernandez-Ilizaliturri FJ; Ellis L
Cell Death Dis; 2015 Dec; 6(12):e2014. PubMed ID: 26658189
[TBL] [Abstract][Full Text] [Related]
17. The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.
Marr AR; Halpin M; Corbin DL; Asemelash Y; Sher S; Gordon BK; Whipp EC; Mitchell S; Harrington BK; Orwick S; Benrashid S; Goettl VM; Yildiz V; Mitchell AD; Cahn O; Mims AS; Larkin KTM; Long M; Blachly J; Woyach JA; Lapalombella R; Grieselhuber NR
Exp Hematol Oncol; 2024 Mar; 13(1):27. PubMed ID: 38438856
[TBL] [Abstract][Full Text] [Related]
18. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
J Virol; 2018 May; 92(10):. PubMed ID: 29343578
[TBL] [Abstract][Full Text] [Related]
19. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.
Hogg SJ; Vervoort SJ; Deswal S; Ott CJ; Li J; Cluse LA; Beavis PA; Darcy PK; Martin BP; Spencer A; Traunbauer AK; Sadovnik I; Bauer K; Valent P; Bradner JE; Zuber J; Shortt J; Johnstone RW
Cell Rep; 2017 Feb; 18(9):2162-2174. PubMed ID: 28249162
[TBL] [Abstract][Full Text] [Related]
20. Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases.
Sahni JM; Gayle SS; Bonk KL; Vite LC; Yori JL; Webb B; Ramos EK; Seachrist DD; Landis MD; Chang JC; Bradner JE; Keri RA
J Biol Chem; 2016 Nov; 291(45):23756-23768. PubMed ID: 27650498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
